Prostate Cancer

Prostate cancer at the BVA looks different from most conditions. The grant rate is 49.9 percent across 597 analyzed cases, well above the overall Board average. The single-largest connection category is presumptive service connection, with herbicide exposure (Agent Orange) accounting for 174 cases and additional Agent Orange exposure paths adding 74 more. Burn-pit exposure under the PACT Act covers another 29 cases. Camp Lejeune contaminated water covers 18.

The structural reason for the grant rate isn't that prostate cancer is medically easier to prove. It's that the regulation does the work the veteran would otherwise have to do. The Agent Orange presumption removes the nexus question for any Vietnam-era veteran with qualifying boots-on-ground service. The PACT Act presumption does the same for post-9/11 veterans exposed to airborne hazards. Once service connection is established, the rating starts at 100 percent during active treatment under DC 7528.

What veterans don't always realize is that the 100 percent rating doesn't last forever. Six months after the last day of active treatment, VA is required to re-evaluate. The post-treatment rating depends entirely on what residuals exist: urinary frequency, voiding dysfunction, sexual dysfunction, anatomical loss. That re-evaluation is where most prostate cancer rating disputes actually happen.

TL;DR

• 597 prostate cancer cases in our BVA dataset. Outcomes: 49.9% granted, 36.5% denied, 13.6% remanded.
• Presumptive service connection grants at 60.1% (248 cases). Direct service connection grants at 47.9% (284 cases). Secondary grants at 41.4% (29 cases).
• The presumptive lane is overwhelmingly Agent Orange: 174 herbicide cases plus 74 Agent Orange cases, plus 29 burn-pit (PACT Act), 18 Camp Lejeune, and 13 radiation exposure cases.
• DC 7528 rates malignant neoplasms of the genitourinary system at 100 percent during the active treatment phase and for six months afterward. After six months without recurrence, the rating drops to the residuals-based level.
• The modal post-treatment rating in our dataset is 40 percent. The 100 percent residuals rating shows up in 40 cases, usually for veterans with severe voiding dysfunction requiring continuous use of absorbent materials.
• Strong nexus opinions grant at 94.4 percent (relevant on the direct lane). Weak nexus grants at 2.3 percent. The opinion-quality cliff is steep but matters less here than for non-presumptive conditions.
• The top denial reason is "severity insufficient" (98 of 218 classified denials, 45 percent). Many of these are residuals-stage cases where the post-treatment voiding or sexual dysfunction documentation didn't support a higher tier.

DC 7528 and the Active-Treatment Floor

Prostate cancer is rated under DC 7528, "Malignant neoplasms of the genitourinary system," in the genitourinary chapter at 38 CFR § 4.115b.

The rating mechanics are unusual. Most diagnostic codes describe a tier ladder based on severity of symptoms. DC 7528 instead describes a temporal sequence: a 100 percent rating during the active treatment phase, mandatory re-evaluation six months after treatment ends, and then a residuals-based rating from that point forward.

The full regulatory text:

"Malignant neoplasms of the genitourinary system: 100. NOTE: Following the cessation of surgical, x-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant."

Three structural features matter here.

The 100 percent floor during active treatment is automatic. As long as the veteran is undergoing surgical, radiation, hormonal, or chemotherapy treatment for prostate cancer, the rating is 100 percent. There's no severity threshold to clear. The diagnosis plus active treatment plus service connection equals 100 percent.

The six-month evaluation is mandatory. VA is required by regulation to schedule a re-examination six months after the last day of active treatment. That examination is what triggers the residuals rating. If VA fails to schedule the examination, the 100 percent rating continues by default until VA actually does the re-examination. This is a procedural protection veterans don't always know about: VA bears the burden of moving the case forward.

The residuals rating is based on what's left after treatment. Most prostate cancer treatment produces some combination of urinary symptoms (frequency, urgency, incontinence, voiding dysfunction), sexual dysfunction (erectile dysfunction is extremely common after radical prostatectomy or radiation), and sometimes bowel symptoms (from radiation proctitis). The residuals rating depends on which symptom is predominant and how it rates under the genitourinary chapter.

The Agent Orange Presumption Drives Most Wins

In our dataset, 248 of 399 presumptive-category cases involve herbicide or Agent Orange exposure. That's 62 percent of the presumptive subset. The Agent Orange framework under 38 USC § 1116 and 38 CFR § 3.309(e) lists prostate cancer as a presumptive condition for veterans with qualifying service during the Vietnam era.

The qualifying service definition has been expanded several times. The most significant recent expansion came from the Blue Water Navy Vietnam Veterans Act of 2019, which extended Agent Orange presumptive eligibility to veterans who served in the offshore waters of Vietnam. Veterans who were previously denied prostate cancer claims under earlier versions of the framework, particularly Blue Water Navy veterans whose claims were denied before the 2019 act, can sometimes file supplemental claims under the expanded definition.

The PACT Act added prostate cancer to the burn-pit presumptive list in 2022. For post-9/11 veterans with qualifying service in covered Southwest Asia and related locations, prostate cancer is now presumptive on the burn-pit basis. The covered locations and time periods are codified in 38 USC § 1119.

Camp Lejeune contaminated water exposure under 38 USC § 1710(e) adds another presumptive lane for veterans stationed at Camp Lejeune between 1953 and 1987. Radiation exposure (atomic veterans, ionizing radiation under § 3.311) covers a smaller subset.

The cumulative effect of these multiple presumptive lanes is that most prostate cancer claims at the BVA are decided on whether the veteran's service fits one of them, not on whether the cancer is related to military service. The presumptive lane grants at 60.1 percent because the regulatory framework does the heavy lifting.

The Six-Month Re-Evaluation and Where Ratings Land Post-Treatment

The most contested period for most prostate cancer claims isn't the initial grant. It's the six-month re-evaluation. The 100 percent rating during active treatment is structurally clean. The residuals rating that comes after is where the rating math gets complicated.

In our dataset, the distribution of post-treatment rating outcomes among granted cases looks like this:

• 0 percent: 1 case
• 10 percent: 7 cases
• 20 percent: 14 cases
• 40 percent: 49 cases (modal)
• 60 percent: 33 cases
• 100 percent: 40 cases

The 40 percent and 60 percent tiers are where most veterans land after the six-month re-evaluation. The 100 percent tier post-treatment is reserved for cases with severe voiding dysfunction requiring continuous absorbent materials and frequent changes, or for cases of recurrence or metastasis that re-trigger the active-treatment 100 percent rating.

The residuals-based rating math depends on which symptom is predominant:

Voiding dysfunction is rated under 38 CFR § 4.115a. The ladder runs from 20 percent (requiring absorbent material changed less than twice per day) to 60 percent (requiring use of an appliance or the wearing of absorbent materials which must be changed more than four times per day). Voiding dysfunction is the most common residual after radical prostatectomy and is the predominant rating basis for most veterans post-treatment.

Urinary frequency rates from 10 percent (daytime voiding interval between two and three hours, or awakening to void twice per night) to 40 percent (daytime voiding interval less than one hour, or awakening to void five or more times per night). Many veterans with mild post-treatment symptoms get rated here rather than under voiding dysfunction.

Renal dysfunction rates from 30 percent to 100 percent based on creatinine levels, blood pressure, and constitutional symptoms. Renal dysfunction is rare as a prostate cancer residual unless treatment produced obstructive complications or there was pre-existing kidney disease.

Erectile dysfunction is rated at 0 percent under current DC 7522, with or without penile deformity. The former 20-percent deformity criterion was removed in the 2021 genitourinary rewrite. When ED is service connected as a prostate-cancer treatment residual, VA should also review possible Special Monthly Compensation under SMC-K (38 USC § 1114(k) and 38 CFR § 3.350). SMC entitlement depends on qualifying service-connected loss or loss of use and should be established from the medical record rather than assumed automatically.

Severity Insufficient: Where the Rating Math Gets Stuck

The largest single denial reason in our dataset is "severity insufficient" at 98 of 218 classified denials. The pattern is consistent.

The veteran is service-connected for prostate cancer. The active treatment phase is over. The six-month re-evaluation establishes residuals. The veteran appeals seeking a higher residuals rating than the regional office assigned. The Board reviews the residuals documentation and concludes the symptoms don't clear the next tier's threshold.

For voiding dysfunction specifically, the rating math turns on the frequency and type of absorbent material use. A veteran wearing a pad that gets changed twice a day is at 20 percent. A veteran changing pads more than four times a day is at 60 percent. The gap between those tiers depends on what the treating clinical record actually documents.

The path to a higher residuals rating usually involves:

• A bladder diary or symptom journal documenting daily voiding frequency and absorbent material use
• Treatment records from a urologist that describe symptom severity in clinically specific terms
• Documentation of any continuous incontinence requiring intermittent self-catheterization or external catheter use
• A C&P examination that engages with the specific tier criteria rather than treating the residuals generically

When the documentation supports the higher tier specifically, the rating moves. When it describes the symptoms in general terms, the rating tends to stay where it was assigned.

What Wins Prostate Cancer Claims at the Board

A few patterns we see consistently in granted prostate cancer cases:

Documented qualifying service for a presumptive lane. DD-214 or unit records showing service in a covered location during a covered period. Vietnam-era boots-on-ground service triggers the Agent Orange presumption. Vietnam offshore-waters service triggers the Blue Water Navy presumption. Post-9/11 Southwest Asia service triggers the PACT Act burn-pit presumption. Camp Lejeune service between 1953 and 1987 triggers that presumptive framework.

Pathology confirmation. The diagnosis itself needs to be supported by a pathology report: biopsy results, surgical pathology, or radiation oncology documentation. Veterans with elevated PSA but no biopsy-confirmed cancer don't qualify for the DC 7528 rating because the malignant neoplasm criterion isn't met.

Active-treatment documentation. The 100 percent active-treatment rating requires documentation that treatment is ongoing. Surgery records, radiation oncology notes, chemotherapy administration records, or hormone therapy prescriptions all qualify. Veterans whose treatment was years ago and who are now in surveillance only don't get the 100 percent rating. They get the residuals rating.

A six-month examination that engages with the residuals criteria. When the C&P examiner explicitly addresses voiding frequency, absorbent material use, and erectile function with clinical specificity, the residuals rating tends to be defensible. Generic examinations produce generic ratings.

SMC-K review. For veterans with service-connected erectile dysfunction following prostate-cancer treatment, the decision should address possible SMC-K under 38 USC § 1114(k) and 38 CFR § 3.350. The evidence should establish the qualifying loss or loss of use; public guidance should not promise an automatic award or hard-code a payment amount that changes over time.

Bottom Line

Prostate cancer is rated under 38 CFR § 4.115b DC 7528. The structural framework gives veterans 100 percent during active treatment and for six months afterward, followed by a mandatory re-evaluation that drops the rating to the residuals level based on voiding dysfunction, urinary frequency, or renal dysfunction. In our BVA dataset of 597 cases, the grant rate is 49.9 percent and the presumptive lane (Agent Orange, PACT Act burn-pit, Camp Lejeune, radiation) drives most of the wins. The post-treatment rating typically lands at 40 or 60 percent for veterans with documented voiding dysfunction, with the 100 percent residuals rating reserved for severe incontinence cases. The most common denial pattern at the residuals stage is "severity insufficient," where the documentation doesn't clearly support the next-higher tier. For service-connected prostate-cancer residuals that include ED, VA should review possible SMC-K under 38 USC § 1114(k) and 38 CFR § 3.350 based on the evidence of loss or loss of use.

Methodology and Limitations

• Data source: 38 CFR § 4.115b DC 7528 (malignant neoplasms of the genitourinary system), 38 CFR § 4.115a (genitourinary residuals rating criteria), 38 USC § 1116 (Agent Orange), 38 USC § 1119 (PACT Act burn pit), 38 USC § 1710(e) (Camp Lejeune), 38 USC § 1114(k) (Special Monthly Compensation), and Claim Raven's analysis of BVA decisions tagged with prostate cancer as the primary condition.
• Sample size: 597 BVA decisions involving prostate cancer as the primary condition. Outcomes split granted 49.9% (298), denied 36.5% (218), remanded 13.6% (81). Connection-type, nexus-quality, denial-reason, and rating-tier breakdowns are coded from the Board's discussion in each decision.
• Limitations: The dataset captures BVA-level decisions. Claims granted at the regional office without appeal aren't in the sample. The Agent Orange presumptive framework has been amended several times and the qualifying-service definitions have expanded; older BVA decisions in the dataset may reflect superseded versions. SMC-K eligibility is a separate analysis from the DC 7528 rating and our dataset doesn't reliably track SMC-K assertion or grant. Residuals ratings post-treatment depend heavily on the specific symptoms documented in each case; the rating-tier distribution we report is a snapshot of where Board cases landed, not a prediction for individual claims. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.